This is a review of the recent IMMhance study – Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis - a phase 3 randomized clinical trial.
The study involved over 500 patients in nine countries and commentary is provided by Dr Diana Rubel, a consultant dermatologist in private practice at Woden Dermatology, Canberra.
Please login below to download this issue (PDF)